Capromorelin

Capromorelin is a growth-hormone secretagogue discussed for stronger appetite and, less consistently, better sleep. Human self-reports include pronounced hunger, bloating, tiredness and suspected insomnia. The appeal is often an alternative to MK-677, but these reports do not establish a better or safer substitute.

What Capromorelin is

• A ghrelin-receptor agonist, also called CP-424391. It stimulates a receptor involved in hunger and growth-hormone release. It is a non-peptide small molecule, not growth hormone itself or a SARM; appearing in a SARM forum does not change its identity. Official context Official context Community guide
• Tartrate is a form of capromorelin; Entyce and Elura are veterinary products. The seed human thread names the tartrate salt. A bottle simply labeled capromorelin does not establish the same formulation or amount of active molecule. Veterinary approval belongs to those animal products and does not approve human self-experimentation. Personal report Official context Official context

Benefits people report

• More hunger after an appetite slump. The February 2020 author described renewed hunger after a severe flu-like illness and a month of poor appetite. A separate October commenter described eating heavily after a first dose. Neither account measures a durable nutritional or muscle-building benefit. Personal report Personal report
• Good sleep in some accounts, insomnia in another. The first-night commenter liked the sleep despite feeling tired and unusually alert beforehand. Sleep-thread contributors also praise it, but discuss other sleep compounds. The seed author instead suspected that capromorelin was keeping them awake. Personal report Personal report Personal report

How people compare it

• MK-677 is the closest community comparison. The seed author felt hunger with capromorelin after reporting no useful appetite response and an upset stomach with MK-677. Their claim that capromorelin is eight times stronger is not a verified human dose conversion; illness, IBS and uncertain products complicate the comparison. Personal report
• “Oral ipamorelin” is shorthand, not an identity. A 2022 poster used that phrase before trying capromorelin. The comparison expresses interest in GH release without injections; it does not make the molecules, doses or outcomes interchangeable. www.reddit.com Community guide

Doses people discuss

• 3 mg twice daily: 6 mg total per day in one report. The seed author later described spacing those amounts by about 12 hours, copied from Reddit. They named tartrate but did not explicitly state the route or whether the milligrams represented salt mass or capromorelin-equivalent mass. This is one account, not a standard range. Personal report
• 6 mg once, and 10 mg in a sleep discussion, are separate accounts. The 6 mg commenter describes a first dose with no explicit route or ongoing schedule. A sleep commenter names 10 mg capromorelin while describing a variable stack; another discusses 5–10 mg oral droppers of capromorelin or MK-677. These are not equivalent regimens or a dose-escalation ladder. Personal report Personal report Personal report
• A 100–200 mg guide claim is research-derived estimation. The 2025 overview itself attributes that oral range to estimates from early research, rather than a personal log. It cannot be combined with the lower firsthand amounts to manufacture a common community range. None of these numbers is a recommendation. Community guide

Half-life

• 2.5 hours is a circulated human-use claim. The sleep-thread commenter gives this figure while comparing capromorelin with MK-677, but links no measurement. A later overview says 2–6 hours across humans and dogs; that mixed-species range is not a verified estimate for a particular human product. Personal report Community guide

Onset: when people notice it

• The first evening in one account; no measured minute-by-minute onset. The 6 mg commenter describes hunger, tiredness and good sleep after the first dose the previous night. A later overview claims appetite within 30–60 minutes but supplies no personal log supporting that precision. It remains a circulated claim. Personal report Community guide

Duration: how long it feels active

• All-day hunger was reported during twice-daily use. That describes the seed author’s day while repeatedly dosing, not the duration of a single dose. The good-sleep account also does not establish how many hours one dose lasts. No reliable post-stop persistence or single-dose appetite window emerged from these inspected reports. Personal report Personal report

Cycles and breaks

• Roughly five days out of seven appears in an ambiguous sleep account. The commenter alternates discussion of capromorelin and MK-677, so this cannot be presented as a clean capromorelin-only schedule. They give no total course length or evidence that the days off prevent tolerance or side effects. Personal report
• 2–8 weeks is an unverified guide claim. The 2025 overview mentions limited logs without identifying them. The first-night comment supplies no completed capromorelin cycle, and its parent thread’s six-week course was MK-677. A dependable capromorelin cycle length or off-period is not established here. Community guide Personal report

What to watch for

• Hunger can come with discomfort and disturbed sleep. Bloating and suspected insomnia accompanied the seed author’s appetite response. The other first-night account combines tiredness with an almost stimulated feeling. Calling it a sleep aid hides that disagreement. Personal report Personal report
• “Without insulin resistance” is contradicted by human research. That expectation appears in a pre-use post. White and colleagues reported fatigue, insomnia and small increases in glucose, HbA1c and insulin-resistance measures. Feeling fine is not evidence that glucose handling is unchanged. www.reddit.com Official context
• Stacked reports cannot establish safe combinations. RAD140 co-use confounds the seed author’s gains. The sleep discussions mix secretagogues with melatonin and other centrally acting compounds, including baclofen or phenibut. Their confident safety assurances are not evidence of safety or of which ingredient helped. Personal report Personal report Personal report
• A named research chemical is not a verified human medicine. The community reports do not independently authenticate bottle contents, concentration or salt basis. The veterinary labels establish specific animal products, not interchangeability with research material or an approved human use. Personal report Personal report Official context

What the human studies add

• A controlled older-adult trial found a limited body-composition signal. White et al. studied 395 adults aged 65–84. At six months, lean mass increased 1.4 kg with capromorelin versus 0.3 kg with placebo. The trial stopped early under predetermined effect criteria; this is not proof of a bodybuilding outcome. Official context
• Measured plasma half-life is separate from hunger duration. Ellis et al. reported mean half-lives at a 50 mg oral study dose of 2.54 hours in able-bodied men and 3.10 hours in men with spinal cord injury. Those capsule-study measurements do not validate low-dose consumer bottles or predict how long hunger or sleep changes feel. Official context

What the accounts reveal together

• The seed author’s benefit and drawbacks are one story. Hunger, bloating, suspected insomnia and later gains are not four independent testimonials. Recent illness and RAD140 co-use remain part of the story, while the author’s proposed IBS-related absorption explanation was never measured. Personal report
• A first-night report is not a completed transformation. The October commenter provides a vivid hunger and sleep impression, not a long-term outcome. The parent author’s disappointing MK-677 course must not be relabeled as capromorelin nonresponse. No clearly documented capromorelin-only null result was found in this inspected sample. Personal report
• The practical disagreement is appetite versus sleep tolerability. One person welcomes hunger after illness; others seek better nights, sometimes amid complicated co-use. Those goals explain why the same compound attracts different expectations. Neither the short reports nor later summaries establish how often it helps, who will respond or whether repeated use is safe. Personal report Personal report Personal report Community guide